Back to Search
Start Over
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
- Source :
- International Journal of Hematology; Nov2021, Vol. 114 Issue 5, p544-553, 10p
- Publication Year :
- 2021
-
Abstract
- Adoptive transfer of in vitro expanded, chimeric antigen receptor (CAR)-redirected CD19-specific T cells can induce dramatic disease regression in patients with leukemia and lymphomas. However, the full potential of this emerging modality is hampered in some cancer settings by a significant rate of therapeutic failure arising from the attenuated engraftment and persistence of CAR-redirected T cells, and tumor relapse following adoptive transfer. Here, we discuss an advanced strategy that facilitates post-infusion in vivo boosting of CAR T cells via CMV vaccination, to mediate durable remission of B cell malignancies by engrafting a CAR molecule onto a CMV-specific T cell. We also discuss a feasible and unique platform for the generation of the CMV-CD19CAR T cells for clinical application. This new approach would overcome multiple challenges in current CAR T cell technology including: short T cell persistence, limited duration of response, and inability to re-stimulate T cells after relapse or persistent disease. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 09255710
- Volume :
- 114
- Issue :
- 5
- Database :
- Complementary Index
- Journal :
- International Journal of Hematology
- Publication Type :
- Academic Journal
- Accession number :
- 152927713
- Full Text :
- https://doi.org/10.1007/s12185-021-03215-6